Ovid Therapeutics Inc. (OVID)
OVID moved a median of -0.32% 30 minutes after news, and +0.37% by the close. How OVID actually reacts to news — the realized, point-in-time move the market made, measured across 239 labeled events over the last three years with zero look-ahead.
OVID’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 30% | 236 |
| 30-min | -0.32% | 40% | 239 |
| 60-min | -0.31% | 43% | 239 |
| to close | +0.37% | 52% | 239 |
| Middle 50% of OVID reactions | -1.81% to +0.98% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 239 |
Half of all Ovid Therapeutics Inc. news events land between -1.81% and +0.98% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OVID reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.90% | 46% | -1.15% |
| Coverage initiations | 29 | -0.75% | 31% | +1.16% |
| Rating reiterations | 37 | +0.18% | 51% | -0.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how OVID ranks against every other measured name →
That’s how OVID usually reacts — get an email when it moves on news →Email me when OVID moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OVID's baseline. Nothing else.
Recent OVID events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ovid Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.07% | -0.71% | |
| Form 10-Q Ovid Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.38% | +5.66% | |
| Form 8-K Ovid Therapeutics Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | +5.66% | |
| Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.38% | +5.66% | |
| Form 8-K Ovid Therapeutics Inc. For: Jul 05 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | +1.87% | |
| Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development | Press release | GlobeNewswire | -1.12% | +1.87% | |
| Form 8-K Ovid Therapeutics Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -3.07% | |
| Ovid Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.86% | +2.48% | |
| Form 8-K Ovid Therapeutics Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | +0.42% | |
| Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors | Press release | GlobeNewswire | -1.60% | +0.42% | |
| Form 10-Q Ovid Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.44% | +3.24% | |
| Form 8-K Ovid Therapeutics Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | +3.24% | |
| Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.44% | +3.24% | |
| Form ARS Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.30% | +0.37% | |
| Form DEF 14A Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +1.30% | +0.37% | |
| Form DEFA14A Ovid Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.30% | +0.37% | |
| Form EFFECT Ovid Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.94% | +4.26% | |
| Form S-3 Ovid Therapeutics Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.17% | -7.32% | |
| Form 8-K Ovid Therapeutics Inc. For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | -0.34% | |
| Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 | Press release | GlobeNewswire | -1.96% | -0.76% | |
| Form 10-K Ovid Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.44% | |
| Form 8-K Ovid Therapeutics Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -3.35% | -3.77% | |
| Form S-8 Ovid Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.44% | |
| Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -3.35% | -3.77% | |
| Ovid Therapeutics Announces Pricing of $60 Million Private Placement | Press release | GlobeNewswire | -3.35% | -3.77% | |
| Ovid Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +5.20% | |
| Form EFFECT Ovid Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.20% | +3.43% | |
| Form 8-K Ovid Therapeutics Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -0.74% | |
| Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) | Press release | GlobeNewswire | +1.48% | -0.74% | |
| Form S-3 Ovid Therapeutics Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.94% | +1.31% | |
| Form 8-K Ovid Therapeutics Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.92% | +1.23% | |
| Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | Press release | GlobeNewswire | -3.37% | -12.36% | |
| Form 10-Q Ovid Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.90% | +8.20% | |
| Form 8-K Ovid Therapeutics Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +5.90% | +8.20% | |
| Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +5.90% | +8.20% | |
| Form DEF 14A Ovid Therapeutics Inc. For: Dec 11 | SEC filing · Form DEF | SEC EDGAR | -2.26% | -0.75% | |
| Form PRE 14A Ovid Therapeutics Inc. For: Dec 11 | SEC filing · Form PRE | SEC EDGAR | -2.50% | -6.88% | |
| Form PREM14A Ovid Therapeutics Inc. For: Dec 11 | SEC filing · Form PREM14A | SEC EDGAR | -2.50% | -6.88% | |
| Form 8-K Ovid Therapeutics Inc. For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | -3.76% | |
| Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile | Press release | GlobeNewswire | -3.00% | -8.00% | |
| Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | Press release | GlobeNewswire | -3.00% | -8.00% | |
| Form 8-K Ovid Therapeutics Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -1.09% | -10.94% | |
| Form 10-Q Ovid Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.19% | +52.62% | |
| Form 8-K Ovid Therapeutics Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | +52.62% | |
| Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.19% | +52.62% | |
| Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | Press release | GlobeNewswire | +6.62% | +2.94% | |
| Form 8-K Ovid Therapeutics Inc. For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -4.08% | -8.16% | |
| Form 8-K Ovid Therapeutics Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -7.57% | -0.79% | |
| Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | Press release | GlobeNewswire | -7.57% | -0.79% | |
| Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | Press release | GlobeNewswire | +0.00% | -3.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OVID section they belong to.
Where else OVID is measured.
OVID earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lixte Biotechnology Holdings, Inc. (LIXT) | 239 | 0.00% | 48% |
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
| Cyclacel Pharmaceuticals, Inc. (CYCC) | 238 | -0.21% | 42% |
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ovid Therapeutics Inc.'s median reaction calculated?
Every labeled OVID news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 239 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of OVID's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OVID's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.